Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

The New Zealand Qualifications Authority and World Education Services Partner on Qualifications Recognition for Migrants with International Education 31-03-2023, 03:00

Amidst Polarizing Global Trends, U.S. B Schools Experience Domestic Demand Rebound 27-10-2023, 19:00